Role of pegylated liposomal doxorubicin in ovarian cancer

J. Tate Thigpen, Carol A. Aghajanian, David S Alberts, Susana M. Campos, Alan N. Gordon, Maurie Markman, D. Scott McMeekin, Bradley J. Monk, Peter G. Rose

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Safe, effective treatments are needed for relapsed ovarian cancer. Goals include improving symptoms, enhancing quality of life, and prolonging survival. The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin. A roundtable meeting of experts in the management of ovarian carcinoma was held to build consensus around the present and future role of pegylated liposomal doxorubicin for ovarian cancer and other gynecologic malignancies. Pegylated liposomal doxorubicin is effective and well tolerated in relapsed ovarian cancer. When compared with topotecan in a phase III randomized trial, pegylated liposomal doxorubicin showed several advantages: improved quality of life, fewer severe adverse events, fewer dose modifications, less hematologic support, and lower total cost per patient. In platinum-sensitive patients, pegylated liposomal doxorubicin also produced a survival advantage. Results from prospective and retrospective studies further demonstrate the improved cardiac safety of pegylated liposomal doxorubicin compared to conventional anthracyclines. Based on survival and toxicity advantages and a once-monthly administration schedule, pegylated liposomal doxorubicin is the first-choice nonplatinum agent for relapsed ovarian cancer. Pegylated liposomal doxorubicin may also have clinical application in combination regimens for platinum-sensitive ovarian cancer, as consolidation/maintenance therapy for ovarian cancer, as a component of first-line therapy for ovarian cancer, and in the treatment of other gynecologic malignancies. Future clinical trials will further define and maximize the role of pegylated liposomal doxorubicin in the treatment of ovarian cancer and other gynecologic malignancies.

Original languageEnglish (US)
Pages (from-to)10-18
Number of pages9
JournalGynecologic Oncology
Volume96
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Ovarian Neoplasms
Platinum
Survival
Quality of Life
Topotecan
Therapeutics
liposomal doxorubicin
Neoplasms
Anthracyclines
Appointments and Schedules
Retrospective Studies
Clinical Trials
Prospective Studies
Carcinoma
Physicians
Safety
Costs and Cost Analysis

Keywords

  • Gynecologic malignancies
  • Ovarian cancer
  • Pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Thigpen, J. T., Aghajanian, C. A., Alberts, D. S., Campos, S. M., Gordon, A. N., Markman, M., ... Rose, P. G. (2005). Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecologic Oncology, 96(1), 10-18. https://doi.org/10.1016/j.ygyno.2004.09.046

Role of pegylated liposomal doxorubicin in ovarian cancer. / Thigpen, J. Tate; Aghajanian, Carol A.; Alberts, David S; Campos, Susana M.; Gordon, Alan N.; Markman, Maurie; McMeekin, D. Scott; Monk, Bradley J.; Rose, Peter G.

In: Gynecologic Oncology, Vol. 96, No. 1, 01.2005, p. 10-18.

Research output: Contribution to journalArticle

Thigpen, JT, Aghajanian, CA, Alberts, DS, Campos, SM, Gordon, AN, Markman, M, McMeekin, DS, Monk, BJ & Rose, PG 2005, 'Role of pegylated liposomal doxorubicin in ovarian cancer', Gynecologic Oncology, vol. 96, no. 1, pp. 10-18. https://doi.org/10.1016/j.ygyno.2004.09.046
Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecologic Oncology. 2005 Jan;96(1):10-18. https://doi.org/10.1016/j.ygyno.2004.09.046
Thigpen, J. Tate ; Aghajanian, Carol A. ; Alberts, David S ; Campos, Susana M. ; Gordon, Alan N. ; Markman, Maurie ; McMeekin, D. Scott ; Monk, Bradley J. ; Rose, Peter G. / Role of pegylated liposomal doxorubicin in ovarian cancer. In: Gynecologic Oncology. 2005 ; Vol. 96, No. 1. pp. 10-18.
@article{1c8e7631c66b4546a850675e81f5afe0,
title = "Role of pegylated liposomal doxorubicin in ovarian cancer",
abstract = "Safe, effective treatments are needed for relapsed ovarian cancer. Goals include improving symptoms, enhancing quality of life, and prolonging survival. The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin. A roundtable meeting of experts in the management of ovarian carcinoma was held to build consensus around the present and future role of pegylated liposomal doxorubicin for ovarian cancer and other gynecologic malignancies. Pegylated liposomal doxorubicin is effective and well tolerated in relapsed ovarian cancer. When compared with topotecan in a phase III randomized trial, pegylated liposomal doxorubicin showed several advantages: improved quality of life, fewer severe adverse events, fewer dose modifications, less hematologic support, and lower total cost per patient. In platinum-sensitive patients, pegylated liposomal doxorubicin also produced a survival advantage. Results from prospective and retrospective studies further demonstrate the improved cardiac safety of pegylated liposomal doxorubicin compared to conventional anthracyclines. Based on survival and toxicity advantages and a once-monthly administration schedule, pegylated liposomal doxorubicin is the first-choice nonplatinum agent for relapsed ovarian cancer. Pegylated liposomal doxorubicin may also have clinical application in combination regimens for platinum-sensitive ovarian cancer, as consolidation/maintenance therapy for ovarian cancer, as a component of first-line therapy for ovarian cancer, and in the treatment of other gynecologic malignancies. Future clinical trials will further define and maximize the role of pegylated liposomal doxorubicin in the treatment of ovarian cancer and other gynecologic malignancies.",
keywords = "Gynecologic malignancies, Ovarian cancer, Pegylated liposomal doxorubicin",
author = "Thigpen, {J. Tate} and Aghajanian, {Carol A.} and Alberts, {David S} and Campos, {Susana M.} and Gordon, {Alan N.} and Maurie Markman and McMeekin, {D. Scott} and Monk, {Bradley J.} and Rose, {Peter G.}",
year = "2005",
month = "1",
doi = "10.1016/j.ygyno.2004.09.046",
language = "English (US)",
volume = "96",
pages = "10--18",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Role of pegylated liposomal doxorubicin in ovarian cancer

AU - Thigpen, J. Tate

AU - Aghajanian, Carol A.

AU - Alberts, David S

AU - Campos, Susana M.

AU - Gordon, Alan N.

AU - Markman, Maurie

AU - McMeekin, D. Scott

AU - Monk, Bradley J.

AU - Rose, Peter G.

PY - 2005/1

Y1 - 2005/1

N2 - Safe, effective treatments are needed for relapsed ovarian cancer. Goals include improving symptoms, enhancing quality of life, and prolonging survival. The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin. A roundtable meeting of experts in the management of ovarian carcinoma was held to build consensus around the present and future role of pegylated liposomal doxorubicin for ovarian cancer and other gynecologic malignancies. Pegylated liposomal doxorubicin is effective and well tolerated in relapsed ovarian cancer. When compared with topotecan in a phase III randomized trial, pegylated liposomal doxorubicin showed several advantages: improved quality of life, fewer severe adverse events, fewer dose modifications, less hematologic support, and lower total cost per patient. In platinum-sensitive patients, pegylated liposomal doxorubicin also produced a survival advantage. Results from prospective and retrospective studies further demonstrate the improved cardiac safety of pegylated liposomal doxorubicin compared to conventional anthracyclines. Based on survival and toxicity advantages and a once-monthly administration schedule, pegylated liposomal doxorubicin is the first-choice nonplatinum agent for relapsed ovarian cancer. Pegylated liposomal doxorubicin may also have clinical application in combination regimens for platinum-sensitive ovarian cancer, as consolidation/maintenance therapy for ovarian cancer, as a component of first-line therapy for ovarian cancer, and in the treatment of other gynecologic malignancies. Future clinical trials will further define and maximize the role of pegylated liposomal doxorubicin in the treatment of ovarian cancer and other gynecologic malignancies.

AB - Safe, effective treatments are needed for relapsed ovarian cancer. Goals include improving symptoms, enhancing quality of life, and prolonging survival. The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin. A roundtable meeting of experts in the management of ovarian carcinoma was held to build consensus around the present and future role of pegylated liposomal doxorubicin for ovarian cancer and other gynecologic malignancies. Pegylated liposomal doxorubicin is effective and well tolerated in relapsed ovarian cancer. When compared with topotecan in a phase III randomized trial, pegylated liposomal doxorubicin showed several advantages: improved quality of life, fewer severe adverse events, fewer dose modifications, less hematologic support, and lower total cost per patient. In platinum-sensitive patients, pegylated liposomal doxorubicin also produced a survival advantage. Results from prospective and retrospective studies further demonstrate the improved cardiac safety of pegylated liposomal doxorubicin compared to conventional anthracyclines. Based on survival and toxicity advantages and a once-monthly administration schedule, pegylated liposomal doxorubicin is the first-choice nonplatinum agent for relapsed ovarian cancer. Pegylated liposomal doxorubicin may also have clinical application in combination regimens for platinum-sensitive ovarian cancer, as consolidation/maintenance therapy for ovarian cancer, as a component of first-line therapy for ovarian cancer, and in the treatment of other gynecologic malignancies. Future clinical trials will further define and maximize the role of pegylated liposomal doxorubicin in the treatment of ovarian cancer and other gynecologic malignancies.

KW - Gynecologic malignancies

KW - Ovarian cancer

KW - Pegylated liposomal doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=10044274225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044274225&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.09.046

DO - 10.1016/j.ygyno.2004.09.046

M3 - Article

C2 - 15589573

AN - SCOPUS:10044274225

VL - 96

SP - 10

EP - 18

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -